UK regulator gives nod to Amgen's Mimpara

13 November 2006

USA-based biotechnology firm Amgen says that the UK's National Institute for Health and Clinical Excellence (NICE), the agency that approves drugs for the National Health Service in England and Wales, has issued a positive Final Appraisal Document regarding its drug Mimpara (cinacalcet) in the treatment of severe secondary hyperparathyroidism. The company said that previous studies demonstrated that patients treated with the agent, in addition to the standard therapy, are less likely to experience bone fractures and cardiovascular hospitalization, than those on placebo plus the standard regimen (Marketletter July 24).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight